College of Health, Medicine and Wellbeing, University of Newcastle, Callaghan, New South Wales, Australia.
Hunter Medical Research Institute, New South Wales, Australia.
Acta Obstet Gynecol Scand. 2024 Apr;103(4):729-739. doi: 10.1111/aogs.14530. Epub 2023 Mar 13.
Pregnancy-associated gynecological cancer (PAGC) refers to cancers of the ovary, uterus, fallopian tube, cervix, vagina, and vulva diagnosed during pregnancy or within 12 months postpartum. We aimed to describe the incidence of, and perinatal outcomes associated with, invasive pregnancy-associated gynecological cancer.
We conducted a population-based historical cohort study using linked data from New South Wales, Australia. We included all women who gave birth between 1994 and 2013, with a follow-up period extending to September 30, 2018. Three groups were analyzed: a gestational PAGC group (women diagnosed during pregnancy), a postpartum PAGC group (women diagnosed within 1 year of giving birth), and a control group (women with control diagnosis during pregnancy or within 1 year of giving birth). We used generalized estimation equations to compare perinatal outcomes between study groups.
There were 1 786 137 deliveries during the study period; 70 women were diagnosed with gestational PAGC and 191 with postpartum PAGC. The incidence of PAGC was 14.6/100 000 deliveries and did not change during the study period. Women with gestational PAGC (adjusted odds ratio [aAOR] 6.81, 95% confidence interval [CI] 2.97-15.62) and with postpartum PAGC (aOR 2.65, 95% CI 1.25-5.61) had significantly increased odds of a severe maternal morbidity outcome compared with the control group. Babies born to women with gestational PAGC were more likely to be born preterm (aOR 3.11, 95% CI 1.47-6.59) and were at increased odds of severe neonatal complications (aOR 3.47, 95% CI 1.45-8.31) compared with babies born to women without PAC.
The incidence of PAGC has not increased over time perhaps reflecting, in part, the effectiveness of cervical screening and early impacts of human papillomavirus vaccination programs in Australia. The higher rate of preterm birth among the gestational PAGC group is associated with adverse outcomes in babies born to these women.
妊娠相关妇科癌症(PAGC)是指在怀孕期间或产后 12 个月内诊断出的卵巢、子宫、输卵管、宫颈、阴道和外阴的癌症。我们旨在描述侵袭性妊娠相关妇科癌症的发病率和围产期结局。
我们使用来自澳大利亚新南威尔士州的链接数据进行了一项基于人群的历史队列研究。我们纳入了 1994 年至 2013 年期间分娩的所有女性,随访期截至 2018 年 9 月 30 日。我们分析了三组:妊娠期 PAGC 组(在怀孕期间诊断出的女性)、产后 PAGC 组(在产后 1 年内诊断出的女性)和对照组(在怀孕期间或产后 1 年内诊断出的控制诊断的女性)。我们使用广义估计方程比较研究组之间的围产期结局。
在研究期间,有 1786137 次分娩;70 名女性被诊断为妊娠期 PAGC,191 名女性被诊断为产后 PAGC。PAGC 的发病率为 14.6/100000 分娩,在研究期间没有变化。与对照组相比,患有妊娠期 PAGC(调整后的优势比[aAOR]6.81,95%置信区间[CI]2.97-15.62)和产后 PAGC(aOR 2.65,95%CI 1.25-5.61)的女性发生严重产妇发病率结局的几率显著增加。患有妊娠期 PAGC 的女性所生的婴儿更有可能早产(aOR 3.11,95%CI 1.47-6.59),并且严重新生儿并发症的风险增加(aOR 3.47,95%CI 1.45-8.31)与未患 PAC 的女性所生的婴儿相比。
PAGC 的发病率并未随着时间的推移而增加,这可能反映了部分原因是澳大利亚宫颈筛查的有效性和人乳头瘤病毒疫苗接种计划的早期影响。妊娠期 PAGC 组中早产率较高与这些女性所生婴儿的不良结局有关。